Financials · DCOY

Decoy Therapeutics Inc. (DCOY) financials

For the twelve months ended Sep 30, 2026, Decoy Therapeutics Inc. reported -$16.56M of net income.

Net income, TTM
-$16.56M
Cash
$8.17M
Market cap
$2.1M
Annual revenue$0
FY2016FY2022
Annual net income-$12.52M
FY2016FY2025
Annual free cash flow-$5.40M
FY2016FY2025

DCOY revenue and earnings growth

DCOY revenueQ3 2026$307.4K

QoQ
+35.1%
FY YoY
-100.0%

DCOY revenue was $307.4K in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier and up 35.1% from the prior quarter. For the full fiscal 2022 it was $0, down 100.0% from fiscal 2021.

DCOY net incomeQ3 2026-$2.99M

DCOY net income was -$2.99M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$873.5K a year earlier. For the full fiscal 2025 it was -$12.52M, compared with -$5.58M in fiscal 2024.

DCOY EPSQ3 2026-$3.53

DCOY diluted EPS was -$3.53 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$129.10, compared with -$69.54 in fiscal 2024.

DCOY free cash flowFY2025-$5.40M

DCOY free cash flow was -$5.40M for fiscal 2025 (ended Dec 31, 2025), compared with -$4.53M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue---$0$1.84M$5.23M$3.47M$1.95M$1.27M$1.01M
Cost of revenue-------$430.8K$506.5K$662.7K
Gross profit-------$1.52M$768.0K$347.9K
Research and development$368.2K$770.0K$7.17M$15.84M$8.55M$6.91M$4.02M$1.29M$16.99M$20.38M
Selling, general and admin$3.73M$4.96M$5.72M$7.14M$6.10M$6.11M$7.71M$2.35M$18.50M$19.86M
Operating income-$12.61M-$5.73M-$12.89M-$31.84M-$12.81M-$7.79M-$8.27M-$1.68M-$34.73M-$39.89M
Income tax$0-----$0---
Net income-$12.52M-$5.58M-$12.54M-$31.61M-$12.77M-$7.35M-$6.94M-$1.67M-$34.43M-$39.49M
EPS, basic-$129.10-$69.54-$5533.20-$21427.20-$11116.80-$18000.00-$76320.00-$41760.00-$71640.00-$87480.00
EPS, diluted-$129.10-$69.54-$5533.20-$21427.20-$11116.80-$18000.00-$76320.00-$41760.00-$71640.00-$87480.00
Diluted shares96,96780,1842,267.11,475.3551,149.054432.73990.79542.761479.462450.944

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$10.71M$2.43M$5.90M$12.11M$29.21M$11.12M$3.74M$6.13M$519.3K$22.54M
Short-term investments-------$0$14.13M$38.66M
Receivables----$1.60M$3.90M$0$9.9K$10.4K$12.2K
Inventory-------$186.9K$431.9K$454.1K
Current assets$10.99M$2.99M$6.52M$14.52M$30.16M$15.80M$4.69M$6.38M$34.54M$62.47M
Goodwill---$0$8.87M$8.87M$8.87M$0--
Total assets$11.06M$3.02M$6.59M$14.65M$40.83M$24.93M$13.89M$6.61M$34.99M$63.21M
Current liabilities$5.17M$1.51M-----$1.11M$5.85M$3.89M
Total liabilities$5.17M$1.51M$1.30M$4.27M$2.11M$2.77M$3.31M$7.88M$5.89M$3.90M
Shareholders' equity$5.89M$1.51M$5.29M$10.38M$38.72M$22.16M$10.58M-$1.27M-$2.90M$59.32M

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow-$4.83M-$4.53M-$12.85M-$17.60M-$10.20M-$10.31M-$11.58M$4.18M-$27.72M-$32.05M
Capital expenditures$577.0K$0--$0$2.6K$0$0$113.5K$559.4K
Free cash flow-$5.40M-$4.53M---$10.20M-$10.31M-$11.58M$4.18M-$27.84M-$32.61M
Investing cash flow$764.7K$0$0-$1.50M$0-$2.6K$5.61M$0$24.49M-$12.24M
Financing cash flow$12.34M$1.06M$6.64M$1.99M$28.30M$17.69M$3.58M$1.44M$2.6K$22.1K
Dividends paid-----$0$133.6K$0--
Stock-based compensation$219.1K$273.7K$524.8K$796.8K$559.0K$319.4K$751.6K$31.0K$4.22M$6.57M
Depreciation and amortization$7.2K$4.4K$10.1K$6.7K$19.2K$18.1K$127.4K$16.9K--

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY----100.0%-64.8%51.0%77.6%53.1%26.1%-
Gross margin-------77.9%60.3%34.4%
Operating margin-----696.3%-148.8%-238.5%-86.3%-2724.6%-3946.5%
Net margin-----693.8%-140.5%-200.2%-85.6%-2701.7%-3907.6%
Free cash flow margin-----554.3%-197.1%-334.2%214.1%-2184.1%-3226.7%
Return on equity-212.6%-368.8%-237.2%-304.4%-33.0%-33.2%-65.6%---66.6%
Return on assets-113.2%-184.4%-190.4%-215.7%-31.3%-29.5%-49.9%-25.2%-98.4%-62.5%
Current ratio2.131.98-----5.765.9116.06

Source: XBRL data Decoy Therapeutics Inc. files with the SEC, latest filing dated Nov 12, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-25, first reported Nov 10, 2022; 1-for-8, first reported Aug 9, 2024; 1-for-15, first reported Nov 14, 2025; 1-for-12, first reported Mar 31, 2026.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DCOY peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
DCOY---$16.56M-$2.1M
LLY$86.46B+45.5%$27.58B31.9%$1.30T
JNJ$99.33B+7.8%$16.09B16.2%$656.47B
ABBV$66.01B+10.7%$10.34B15.7%$505.56B
MRK$67.38B+4.9%$2.45B3.6%$339.66B
NVS$54.53B+8.4%$13.98B25.6%$296.16B
AZN$58.74B+8.6%$10.22B17.4%$277.21B
ABT$48.23B+10.0%$4.70B9.7%$180.95B
NVODKK 309.06B+6.4%DKK 102.43B33.1%$174.57B

DCOY FAQ

5 questions
  • Is DCOY profitable?
    No. Decoy Therapeutics Inc. reported a net loss of $16.56M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does DCOY have?
    Decoy Therapeutics Inc. reported $8.17M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is DCOY revenue growing?
    Decoy Therapeutics Inc.'s revenue changed -100.0% in fiscal 2022, to $0.
  • When did DCOY last report financial results?
    The latest statements here come from Decoy Therapeutics Inc.'s 10-Q filed on Nov 12, 2026, covering the period ended Sep 30, 2026.
  • Where does this DCOY financial data come from?
    Quantisnow builds these statements from the structured XBRL data Decoy Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.